Aro Biotherapeutics Appointed Brett Blackman to Board

The Philadelphia-based biotech company added the veteran executive to its leadership team to support growth.

Updated on Sept. 29, 2026 in Biotech

Isometric editorial illustration showing a minimalist atrium with a large, abstract molecular structure, symbolizing corporate growth. — Aro Biotherapeutics has appointed Brett Blackman, an executive from Valo Health, to its board to bolster strategic leadership and platform scaling. AI Illustration. Upload story photo >

Live Poll

Do you trust that new corporate board appointments improve a biotech company's focus on patient needs?

Aro Biotherapeutics has appointed Brett Blackman, the Chief Operating Officer and Chief Business Officer at Valo Health, to its Board of Directors. The addition aims to leverage his extensive experience in scaling biotechnology firms as the company pursues platform expansion.

Why it matters

Appointing an industry veteran with a background in scaling startups provides Aro Biotherapeutics with strategic guidance to navigate its next phase of growth. This move is designed to support the firm as it scales its platform into new disease areas.

Brett Blackman brings 25 years of professional experience in drug discovery to the board. The appointment follows earlier foundational research that produced 10 distinct human disease models.

The players

Brett Blackman

He is the current Senior Vice President, Chief Operating Officer, and Chief Business Officer at Valo Health.

Aro Biotherapeutics

This is a Philadelphia-based biotechnology company focused on developing a new platform for therapeutic delivery.

The details

Aro Biotherapeutics announced the board seat addition through a press release, highlighting Blackman's history in executive leadership. He previously founded HemoShear Therapeutics and held multiple high-level roles at various biotech firms before his current position at Valo Health.

Brett Blackman founded HemoShear Therapeutics in 2008.
Blackman began his tenure at Flagship Pioneering portfolio companies in 2016.
Aro Biotherapeutics officially announced the appointment on September 29, 2026.

Roadmap

This appointment follows a common industry trend of talent rotation among executives who have matured through firms within the Flagship Pioneering venture creation model. It positions Aro Biotherapeutics to scale effectively by integrating leadership expertise honed in the competitive biotech startup ecosystem.

This leadership change provides internal stability as the company works toward developing new therapeutic treatments. Residents and local investors may see a strengthened operational profile for the Philadelphia-based firm as it advances its research programs.

The takeaway

Bringing in experienced leadership from Valo Health underscores the firm's focus on long-term commercial scalability. Investors and stakeholders should watch for how this board addition influences upcoming clinical development priorities.